
Developmental/Behavioral Disorders
Latest News
Latest Videos

More News

ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.

From baseline to final assessment, all 7 matched cerliponase alfa-treated children under 3 years of age maintained a motor score of 3, representing a "grossly normal gait, signifying a delay in disease onset," stated BioMarin.

A laboratory-based assessment shows children aged 18 - 32 months old were less likely to listen to attention prompts or their parent's requests when provided an iPad versus a standard toy.

Investigators therefore concluded that ROAR provides an excellent way to identify children at highest risk of having poor reading skills.

Overall, the findings of the study support the clinical utility of combining trio-WES sequencing with CNV-seq in the etiologic diagnosis and management of early-childhood GDD.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the latest issue of Contemporary Pediatrics and how these articles can be utilized in the everyday practice of PNPs.














